Vitamin D3 and K2: Why They Work Better Together (And How Much K2 You Actually Need)
Vitamin D3 is one of the most widely taken supplements in the world, particularly in northern latitudes where sun exposure is limited for much of the year. Vancouver, Toronto, Seattle — from October to April, meaningful UVB exposure is essentially unavailable.
Most people taking vitamin D3 are not taking K2. There's a reasonable mechanistic case that they should be. Here's what the evidence says.
If you want the evidence-grade summaries, start here:
The Calcium Paradox
Vitamin D3's primary job is increasing calcium absorption from the intestine. More vitamin D = more calcium absorbed from food and supplements. This is largely why vitamin D is so important for bone health.
The problem: increased calcium absorption doesn't automatically mean calcium ends up in bones. Calcium is deposited throughout the body — in bones and teeth, where you want it, and potentially in soft tissues (blood vessels, kidneys) where you don't.
Vitamin K2's role: K2 activates two critical proteins:
- Osteocalcin — a protein produced by bone-forming cells that binds calcium and incorporates it into bone matrix
- Matrix GLA protein (MGP) — a protein that actively prevents calcium from depositing in arterial walls
Both proteins require carboxylation by vitamin K2 to function. Without adequate K2, these proteins remain inactive.
The hypothesis: high-dose vitamin D without adequate K2 may increase calcium absorption while leaving the proteins that direct that calcium inadequately activated. This is sometimes called the “calcium paradox” — more calcium absorbed, but without K2, its destination is less certain.
The Evidence
Vitamin D for bone health: Grade A for deficiency correction and fracture prevention in deficient populations. Grade B for immune function and mood.
Vitamin K2 for bone density: Grade B. Multiple RCTs using vitamin K2 (MK-4 and MK-7 forms) show improvements in bone mineral density in post-menopausal women and older adults.
The D3 + K2 combination: The synergy is mechanistically well-supported. Direct long-term RCT evidence on hard outcomes (arterial calcification reduction, fracture rates) is developing — the mechanism is strong; the outcomes data is building.
On arterial calcification specifically: MGP is a strong inhibitor of arterial calcification, and its function requires K2. Population studies in Rotterdam and Maastricht found higher dietary vitamin K2 intake (not K1) associated with lower cardiovascular disease risk and lower rates of aortic calcification.
Vitamin K2 Forms: MK-4 vs. MK-7
MK-4 and MK-7 are both vitamin K2 but behave differently in the body.
MK-4 (menaquinone-4):
- Short biological half-life (hours)
- Requires multiple daily doses to maintain activity
- Typical research dose: 1,500mcg (1.5mg) three times daily = 4,500mcg/day total
MK-7 (menaquinone-7):
- Long biological half-life (~3 days)
- Once-daily dosing maintains steady-state levels
- Typical effective dose: 100–200mcg/day
Which to take: MK-7 at 100–200mcg/day is the practical choice for most people.
What to look for on the label: “Vitamin K2 as MK-7” / “menaquinone-7.” Not just “vitamin K” (often K1).
How Much K2 With How Much D3?
There’s no established dosing ratio and no consensus guideline. Here’s practical guidance (not a clinical recommendation):
- Standard supplemental vitamin D3 (1,000–2,000 IU/day): 100mcg MK-7 is likely sufficient
- Higher-dose vitamin D3 (3,000–5,000 IU/day): 100–200mcg MK-7 is the commonly recommended range
- Therapeutic vitamin D doses (>5,000 IU/day): use combined supplementation under medical guidance and monitor levels
Combined supplements: Many high-quality D3 + K2 products exist. Look for D3 + MK-7 specifically, with the MK-7 content clearly labeled.
The Vancouver / Northern Latitude Context
From approximately October to April, the sun angle in Vancouver is too low for meaningful UVB to reach the skin — even on clear days. Vitamin D production requires UVB radiation at a sun angle >35° above the horizon.
The practical implication: most people in northern latitudes need supplemental vitamin D for at least half the year, often year-round. Serum 25(OH)D testing is the only way to know your baseline and monitor supplementation.
Testing before supplementing: If you're going to supplement at higher doses (>2,000 IU/day), testing baseline and follow-up levels is worthwhile. Vitamin D toxicity from supplementation is rare but real at very high doses (>10,000 IU/day for extended periods).
The Critical Interaction: Vitamin K + Warfarin
One significant exception to the “take D3 + K2 together” recommendation:
If you are on warfarin (Coumadin): do not supplement vitamin K2 without direct involvement from your anticoagulation prescriber.
Warfarin works by blocking vitamin K-dependent clotting factor synthesis. Vitamin K2 supplementation opposes warfarin's mechanism and can reduce its anticoagulant effect.
This interaction does not apply to newer anticoagulants (apixaban, rivaroxaban, dabigatran) — but for warfarin specifically, K2 supplementation requires prescriber coordination.
If you want to check this (and other) supplement-drug interactions for your current stack:
The Protocol
For most adults in northern latitudes supplementing for general health:
| Recommendation | |
|---|---|
| Vitamin D3 dose | 2,000 IU/day (general health); test and adjust for deficiency correction |
| Vitamin K2 form | MK-7 (menaquinone-7) |
| Vitamin K2 dose | 100–200mcg/day |
| Timing | With the fattiest meal of the day (both are fat-soluble) |
| Testing | 25(OH)D baseline + 3 months post-supplementation if changing dose |
| Warfarin users | Consult prescriber before adding K2 |
What This Doesn't Cover
Vitamin D has other roles beyond calcium/bone — immune function, mood, inflammation — where K2 doesn't play a direct role. If you're supplementing vitamin D primarily for immune function or mood support, the K2 rationale is less central (though taking K2 alongside high-dose D3 remains a low-risk addition given the bone health mechanism).
Sources
- Gast GC, et al. “A high menaquinone intake reduces the incidence of coronary heart disease.” Nutr Metab Cardiovasc Dis. 2009. (PMID: 19179058)
- Knapen MH, et al. “Three-year low-dose menaquinone-7 supplementation helps decrease bone loss.” Osteoporos Int. 2013. (PMID: 23525894)
- van Ballegooijen AJ, et al. “The synergistic interplay between vitamins D and K for bone and cardiovascular health.” Int J Endocrinol. 2017. (PMID: 29138634)
- Holick MF. “Vitamin D deficiency.” N Engl J Med. 2007. (PMID: 17634462)
Evidence grades updated March 2026. This post is for informational purposes and is not medical advice.
Build Your Evidence-Based Stack
Get personalized, evidence-graded supplement recommendations powered by AI.
Start Building